HC Wainwright Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $60.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 257.57% from the stock’s previous close.

A number of other research firms also recently issued reports on URGN. LADENBURG THALM/SH SH upped their price target on shares of UroGen Pharma from $48.00 to $53.50 and gave the company a “buy” rating in a research note on Friday, June 14th. Oppenheimer increased their target price on shares of UroGen Pharma from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, June 14th.

UroGen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $16.78 on Monday. The firm has a fifty day moving average price of $14.35 and a 200 day moving average price of $15.25. UroGen Pharma has a fifty-two week low of $8.69 and a fifty-two week high of $24.13. The firm has a market cap of $393.49 million, a price-to-earnings ratio of -4.94 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.04). The company had revenue of $18.78 million for the quarter, compared to the consensus estimate of $20.73 million. As a group, research analysts predict that UroGen Pharma will post -3.6 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Mark Schoenberg sold 5,153 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $13.08, for a total value of $67,401.24. Following the transaction, the insider now owns 144,284 shares of the company’s stock, valued at approximately $1,887,234.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 11.13% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. RA Capital Management L.P. bought a new position in UroGen Pharma during the 3rd quarter worth about $20,787,000. RTW Investments LP grew its holdings in UroGen Pharma by 101.4% during the 4th quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock worth $25,902,000 after acquiring an additional 869,344 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of UroGen Pharma in the 1st quarter valued at about $4,008,000. Superstring Capital Management LP bought a new stake in shares of UroGen Pharma in the 4th quarter valued at about $3,831,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of UroGen Pharma in the 3rd quarter valued at about $1,824,000. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.